Market Closed -
Other stock markets
|
Pre-market 07:00:13 am | |||
23.53 USD | -0.76% | 23.42 | -0.47% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 11 | Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.92% | 6.94B | B | ||
-2.26% | 103B | B+ | ||
+1.41% | 95.71B | B+ | ||
+0.90% | 22.02B | B | ||
-17.84% | 20.9B | B+ | ||
-9.44% | 17.85B | A- | ||
-42.83% | 16.21B | A- | ||
-17.63% | 15.52B | B | ||
+4.55% | 13.86B | C+ | ||
+32.11% | 12.04B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EXEL Stock
- Ratings Exelixis, Inc.